Allergic bronchopulmonary aspergillosis management widens past corticosteroids and itraconazole
Biologic therapy in ABPA, novel azole maturity, and structured diagnostic-and-monitoring pathways are reshaping allergic bronchopulmonary aspergillosis management.
Allergic bronchopulmonary aspergillosis (ABPA) has been a corticosteroid and itraconazole category. Anti-IgE (omalizumab) and anti-IL-5 pathway therapy (mepolizumab, benralizumab) are increasingly used in ABPA based on the cross-condition eosinophilic biologic class maturity (covered in earlier rounds), novel azole formulations and isavuconazole alternatives are widening, and structured diagnostic-and-monitoring pathways are formalising. The category is acquiring biologic-pathway commercial integration with the broader severe-asthma frame.
Continue reading
Full intelligence on PanaceaIntel
PatientSpotlight publishes the headline framing. The full brief, the editorial takeaway, and the source list sit on PanaceaIntel for entitled clients.
New to PanaceaIntel? Request access and the team will reply within one working day.